Trials / Completed
CompletedNCT00582985
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Tracon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
Detailed description
In addition to safety, this study will also evaluate pharmacokinetics, tumor response and anti-TRC105 antibody formation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRC105 chimeric anti-CD105 antibody | TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2007-12-28
- Last updated
- 2012-03-05
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00582985. Inclusion in this directory is not an endorsement.